Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 6,383,169	$ 2,112,806
Operating expenses:
Product cost of sales	6,401,018
Research and development	23,461,400	16,455,278
General and administrative	21,130,879	16,828,229
Goodwill impairment loss		1,452,338
Amortization of intangible asset	1,030,625
In-process research and development impairment	3,500,000	2,366,000
Change in fair value of contingent consideration	(3,452,015)	430,000
Total operating expenses	52,071,907	37,531,845
Loss from operations	(45,688,738)	(35,419,039)
Change in fair value of warrant liability	11,020	22,758
Interest income	987,247	815,316
Unrealized loss on available-for-sale securities	(1,701,428)	(842,538)
Other expense, net	(759,235)	(123,278)
Total non-operating loss	(1,462,396)	(127,742)
Net loss before income taxes	(47,151,134)	(35,546,781)
Income tax benefit	3,288,937	145,974
Net loss	(43,862,197)	(35,400,807)
Net loss - non-controlling interest	(427,491)	(329,339)
Net loss attributable to NightHawk Biosciences, Inc.	$ (43,434,706)	$ (35,071,468)
Net loss per share, basic (in dollars per share)	$ (1.70)	$ (1.41)
Net loss per share, diluted (in dollars per share)	$ (1.70)	$ (1.41)
Weighted-average common shares outstanding, basic (in shares)	25,606,326	24,913,942
Weighted-average common shares outstanding, diluted (in shares)	25,606,326	24,913,942
Comprehensive loss:
Net loss	$ (43,862,197)	$ (35,400,807)
Unrealized gain on foreign currency translation	119,865	98,115
Total comprehensive loss	(43,742,332)	(35,302,692)
Comprehensive loss attributable to non-controlling interest	(427,491)	(329,339)
Comprehensive loss - NightHawk Biosciences, Inc.	(43,314,841)	(34,973,353)
Product sales
Revenue:
Total revenue	5,980,993
Grant and contract revenue
Revenue:
Total revenue	$ 402,176	$ 2,112,806